Abstract 125P
Background
Esophageal cancer (EC) takes, all over the world, 9th place in the structure of new incidents of malignant tumors, amounting to 572034 registered cases and 6th place in the structure of mortality rate, taking 508585 lives annually. According to statistical data, EC develops much more often in men than in women (70% of new cases have developed in men), and people over 70 make up about 40% of the total number of cases, with a peak incidence occurring at the age of 50-60 years. However, these indicators vary by geographic region. So, for example, the highest incidence is found in East Asia, eastern and southern Africa (8.1-23.6‱), while the lowest rate belongs to central America. The aim of the research was to study the dynamics of changes in the incidence trends in the Republic of Uzbekistan over the past 20 years.
Methods
A meta-analysis of the detection of mortality of esophageal cancer (EC) for all patients with the verified diagnosis was performed. For the period from 2000 - 2019, 18129 patients were identified in the Uzbekistan and the average incidence of EC was 2.8 per 100 thousand of the population. Of these 8283 (45.7%) were treated at the clinic of NCC, in particular, 1174 (14.2%) patients were operated.
Results
The analysis revealed that in 2000, in 0,4% and 18,2% of cases, patients had I - II stage disease, in 64,5% of cases – III, and in 18,2% of cases – IV clinical stage, in 2009, 0,5% and 22,8% of cases, patients had I - II stage disease, in 54,4% of cases – III, and in 16,4% of cases - IV clinical stage, and in 2019, 3,3% and 33,7% of cases patients had I – II stage disease, in 44,5% of cases - III, and in 12,5% of cases - IV clinical stage.
Conclusions
A relative decrease in the mortality rate over the study period was also revealed: from 2.7% in 2000 to 1.8% in 2019. There has been a decrease in the mortality trend - 2000, 2009 and 2019, 2.2, 1.7 and 1.1, respectively. At the same time, 5-year survival was relatively stable and varied in the range of 12.1% - 27.3%. The largest number of patients was identified in the clinical stage III of the disease and ranged from 42.2 to 67%, respectively.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Republican Specialized Oncology and Radiology Research - Practice Medical Center (National Cancer Center).
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
403P - Clinical profile, practice pattern and outcomes in ALK-positive lung cancer: Real-world data from India
Presenter: Akhil Kapoor
Session: e-Poster Display Session
404P - Financial toxicity in patients with advanced lung cancer treated with immunotherapy: Has it an effect on the clinical decision?
Presenter: Jia-Hui Weng
Session: e-Poster Display Session
405P - Promising efficacy as combination therapy of DFP-14323, protease inhibitor, with EGFR-TKI in patients with metastatic NSCLC harboring EGFR mutation
Presenter: Hiroshige Yoshioka
Session: e-Poster Display Session
406P - Anti-PD-1 versus anti-PD-L1 inhibitors in first-line therapy non-small-cell lung cancer: A systematic review and meta-analysis
Presenter: Angelo Brito
Session: e-Poster Display Session
407P - Integrating histologic and genomic characteristics to predict tumour mutation burden of early-stage non-small cell lung cancer
Presenter: Yuan Qiu
Session: e-Poster Display Session
408P - Integrated chemotherapy with EGFR receptor tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutation
Presenter: Julia Maevskaya
Session: e-Poster Display Session
409P - Effect of transdermal granisetron on prevention of nausea and vomiting during chemotherapy of lung cancer
Presenter: Haifeng Qin
Session: e-Poster Display Session
410P - Frequency and spectrum of primary resistance mechanism in Chinese ALK+ non-small cell lung cancer patients progressing on crizotinib: A multicenter study
Presenter: Wen-xian Wang
Session: e-Poster Display Session
411P - Impact of pre-treatment AXL expression on osimertinib efficacy in patients with non-small cell lung cancer with EGFR mutation
Presenter: Yoshihiko Taniguchi
Session: e-Poster Display Session
412P - Treatment patterns and selection criteria for advanced non-small cell lung cancer (NSCLC) patients unfit for platinum-based first-line therapy: Results of the MOON-OSS observational trial
Presenter: Andrea Camerini
Session: e-Poster Display Session